Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (Nasdaq: PSTV) will release its Second Quarter Fiscal Year 2020 financial results after market close on August 10, 2020. A conference call at 5:00 PM ET will provide insights into the results and a business update. The company focuses on developing radiotherapeutics using its nanotechnology platform to target rare cancers. This technology enhances drug delivery and formulation for improved patient safety and convenience.
Plus Therapeutics (Nasdaq: PSTV) announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial, evaluating Rhenium NanoLiposomes (RNL™) in adults with recurrent glioblastoma (GBM). The trial has expanded to a second site at UT Southwestern Medical Center, enrolling 15 patients across five cohorts, with six more planned. RNL aims to deliver radiation doses up to 25 times greater than conventional methods, with further developments anticipated including cohort 6, completion of enrollment, and potential orphan drug designations.
Plus Therapeutics (PSTV) announced its participation in the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day, scheduled for July 30, 2020, at 10:00 p.m. EST. Dr. Marc Hedrick will lead the presentation and engage with investors during the session. Attendees can register for free tickets to join the live event or opt for a Video on Demand Ticket. A replay will be available on the company's website a week later for those unable to attend live. Plus Therapeutics specializes in developing radiotherapeutics targeting rare cancers using a unique nanotechnology platform.
On July 6, 2020, Plus Therapeutics, Inc. (PSTV) announced the approval of stock options for key executives. Dr. Gregory Stein was granted options for 40,000 shares at an exercise price of $2.11, and Andrew Sims received the same number at $2.23, both vesting over four years. This decision aligns with the company's 2015 New Employee Incentive Plan, which was recently amended to allow additional shares for inducement awards. Plus Therapeutics is focused on developing innovative cancer therapies.
Plus Therapeutics (PSTV) reported its Q1 2020 financial results with a net loss of $1.1 million, or $0.28 per share, showing improvement from a $2.5 million loss in Q1 2019. Operating cash usage decreased to $1.5 million compared to $3.3 million last year. The company has secured a licensing agreement for rare cancer therapies, including Rhenium-186-chelated NanoLiposome for glioblastoma, with potential milestone payments totaling $136.5 million. Plus Therapeutics ended the quarter with $16.1 million in cash and emphasizes ongoing clinical trials and pipeline expansion.
Plus Therapeutics (PSTV) announced a live webinar, led by Dr. Andrew Brenner, on a new radiotherapy for recurrent glioblastoma scheduled for May 17, 2020. This initiative is part of the Musella Foundation Webinar Series and aims to educate patients and raise awareness during Brain Tumor Awareness Month. Plus Therapeutics recently licensed a radiolabeled nanoliposome drug portfolio, with its lead asset, Rhenium NanoLiposome (RNL™), supported by a $3.7 million NIH/NCI grant. The platform focuses on delivering high-dose radiation directly to brain tumors via advanced delivery techniques.
Plus Therapeutics (PSTV) announced the closing of a licensing agreement for rare cancer product candidates from NanoTx Therapeutics. The deal involves an upfront payment of $400,000 in cash and $300,000 in stock, with potential milestone payments totaling $136.5 million and royalties on U.S. and European sales. The lead asset, Rhenium-186-chelated NanoLiposome (RNL™), is under Phase 1 clinical trials for recurrent glioblastoma, aiming to deliver radiation doses significantly higher than traditional methods. Plus aims to address unmet medical needs in oncology with significant revenue opportunities.